Kiniksa Pharmaceuticals International Plc Revenue Growth Rates (KNSA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Kiniksa Pharmaceuticals International Plc  (NASDAQ: KNSA)
 

KNSA's Revenue Growth by Quarter and Year

Kiniksa Pharmaceuticals International Plc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

KNSA Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 214.27
FY 214.27

KNSAs Annual Revenue
Kiniksa Pharmaceuticals International Plc's Revenue in the fiscal year 2025 $ 677.56 millions
Kiniksa Pharmaceuticals International Plc's Revenue in the fiscal year 2024 $ 423.24 millions
Kiniksa Pharmaceuticals International Plc's Revenue in the fiscal year 2023 $ 270.26 millions
Kiniksa Pharmaceuticals International Plc's Revenue in the fiscal year 2022 $ 220.18 millions
Kiniksa Pharmaceuticals International Plc's Revenue in the fiscal year 2021 $ 38.54 millions




KNSA Revenue first quarter 2026 Y/Y Growth Comment
Kiniksa Pharmaceuticals International Plc reported Revenue rise of 55.5% year on year in the first quarter 2026, to $ 214.27 millions, this is lower than Kiniksa Pharmaceuticals International Plc's recent average Revenue rise of 73.61%.

Looking into first quarter 2026 results within Major Pharmaceutical Preparations industry 8 other companies have achieved higher Revenue growth. While Kiniksa Pharmaceuticals International Plc' s Revenue jump of 55.5% ranks overall at the positon no. 210 in the first quarter 2026.


KNSA Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 64.95 % 46.93 % 34.78 %
3rd Quarter September - 61.18 % 67.35 % -32.37 %
2nd Quarter June - 44.34 % 51.99 % 165 %
1st Quarter March 55.5 % 72.54 % 65.17 % 50.2 %
FY   - 60.09 % 56.6 % -

Financial Statements
Kiniksa Pharmaceuticals International Plc's first quarter 2026 Revenue $ 214.27 millions KNSA's Income Statement
Kiniksa Pharmaceuticals International Plc's first quarter 2025 Revenue $ 137.79 millions Quarterly KNSA's Income Statement


KNSA Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 11.76 % 9.21 % 24.38 %
3rd Quarter September - 15.34 % 3.3 % -6.18 %
2nd Quarter June - 13.8 % 36.03 % 47.82 %
1st Quarter March 6 % 12.44 % -4.24 % -21.86 %
FY (Year on Year)   - 60.09 % 56.6 % -


Back to KNSA Growth rate Comparisons >> Back to KNSA Growth rate Comparisons >>


Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #9
Healthcare Sector #25
Overall #210

Revenue Y/Y Growth Statistics
High Average Low
234.12 % 73.61 % 20.69 %
(Mar 31 2023)   (Jun 30 2024)
Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #9
Healthcare Sector #25
Overall #210
Revenue Y/Y Growth Statistics
High Average Low
234.12 % 73.61 % 20.69 %
(Mar 31 2023)   (Jun 30 2024)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Kiniksa Pharmaceuticals International Plc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
267.55 % 28.7 % -37.58 %
(Sep 30 2022)  


KNSA's I. Quarter Q/Q Revenue Comment
Kiniksa Pharmaceuticals International Plc achieved in the I. Quarter 2026 below company average Revenue increase of 6% quarter on quarter, to $ 214.27 millions.

Within Major Pharmaceutical Preparations industry only one company achieved higher sequential Revenue growth. While Kiniksa Pharmaceuticals International Plc's Revenue growth quarter on quarter, overall rank is 184.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #2
Healthcare Sector #10
Overall #184
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #2
Healthcare Sector #10
Overall #184
Revenue Q/Q Growth Statistics
High Average Low
267.55 % 28.7 % -37.58 %
(Sep 30 2022)  


KNSA's I. Quarter Q/Q Revenue Comment
Kiniksa Pharmaceuticals International Plc achieved in the I. Quarter 2026 below company average Revenue increase of 6% quarter on quarter, to $ 214.27 millions.

Within Major Pharmaceutical Preparations industry only one company achieved higher sequential Revenue growth. While Kiniksa Pharmaceuticals International Plc's Revenue growth quarter on quarter, overall rank is 184.


Kiniksa Pharmaceuticals International Plc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)		 12 Months Ending
(Mar 31 2025)
Cumulative Revenue 12 Months Ending $ 754.05 $ 677.56 $ 597.97 $ 529.33 $ 481.17
Y / Y Revenue Growth (TTM) 56.71 % 60.09 % 55.68 % 56.18 % 59.45 %
Year on Year Revenue Growth Overall Ranking # 21 # 118 # 24 # 41 # 56
Seqeuential Revenue Change (TTM) 11.29 % 13.31 % 12.97 % 10.01 % 13.69 %
Seq. Revenue Growth (TTM) Overall Ranking # 210 # 864 # 185 # 87 # 217


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Mar 31 2026 period, Kiniksa Pharmaceuticals International Plc's cumulative twelve months Revenue were $ 754 millions, company would post below average annual Revenue growth of 13.69% year on year, if the fiscal year would end at Mar 31 2026.
A slow-down in the Kiniksa Pharmaceuticals International Plc's Revenue growth from the 202.13% growth in Dec 31 2025.

Among companies within the Healthcare sector 4 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 21, from total ranking in previous quarter at 118.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 9
Healthcare Sector # 5
Overall # 21

Revenue TTM Y/Y Growth Statistics
High Average Low
234.12 %
 73.61 %
20.69 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 9
Sector # 25
S&P 500 # 210
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Mar 31 2026 period, Kiniksa Pharmaceuticals International Plc's cumulative twelve months Revenue were $ 754 millions, company would post below average annual Revenue growth of 20.69% year on year, if the fiscal year would end at Mar 31 2026.
A slow-down in the Kiniksa Pharmaceuticals International Plc's Revenue growth from the 202.13% growth in Dec 31 2025.

Among companies within the Healthcare sector 4 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 21, from total ranking in previous quarter at 118.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 9
Healthcare Sector # 5
Overall # 21

Revenue TTM Y/Y Growth Statistics
High Average Low
234.12 %
73.61 %
20.69 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 9
Sector # 25
S&P 500 # 210




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
KNSA's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Mar 31 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2026
Alnylam Pharmaceuticals Inc 96.43%$ 96.432 millions
Abcellera Biologics Inc 96.34%$ 96.340 millions
Viridian Therapeutics Inc 95.83%$ 95.833 millions
Alamar Biosciences Inc 94.46%$ 94.462 millions
Bioage Labs Inc 91.04%$ 91.041 millions
Tenon Medical Inc 89.94%$ 89.945 millions
Vaxart Inc 87.90%$ 87.905 millions
Cannapharmarx Inc 87.12%$ 87.124 millions
Ionis Pharmaceuticals Inc 86.98%$ 86.982 millions
Picard Medical Inc 85.48%$ 85.484 millions
Therapeuticsmd Inc 84.22%$ 84.224 millions
Rhythm Pharmaceuticals Inc 83.81%$ 83.806 millions
Billiontoone Inc 83.33%$ 83.329 millions
Upstream Bio Inc 82.69%$ 82.686 millions
Neuraxis Inc 79.52%$ 79.520 millions
Fennec Pharmaceuticals Inc 72.64%$ 72.643 millions
Scilex Holding Company72.12%$ 72.122 millions
Gossamer Bio Inc 71.45%$ 71.453 millions
Innovative Eyewear Inc 70.20%$ 70.200 millions
Tg Therapeutics Inc 69.56%$ 69.556 millions
Seastar Medical Holding Corp68.94%$ 68.942 millions
Crispr Therapeutics Ag68.55%$ 68.555 millions
Bridgebio Pharma Inc 66.78%$ 66.775 millions
Aquestive Therapeutics Inc 65.67%$ 65.665 millions
Beyond Air Inc 65.54%$ 65.538 millions
Coherus Oncology inc 61.99%$ 61.995 millions
Beta Bionics Inc 61.67%$ 61.670 millions
Apellis Pharmaceuticals Inc 60.85%$ 60.851 millions
Arcutis Biotherapeutics Inc 60.07%$ 60.067 millions
Biocorrx Inc 59.04%$ 59.037 millions


About Kiniksa Pharmaceuticals International Plc Revenue Growth Rates (KNSA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Kiniksa Pharmaceuticals International Plc (CIK 1730430).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104659-26-087545
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Kiniksa Pharmaceuticals International Plc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.